Ez-PAVE finds no outcome advantage for upfront ezetimibe when LDL targets are actively managed
Starting treatment with a statin alone or with a statin plus ezetimibe led to similar three-year cardiovascular outcomes in adults with established atherosclerotic cardiovascular disease when clinicians adjusted therapy to reach a prespecified LDL cholesterol target. The result matters because it separates two ideas that are often bundled together in practice: how fast LDL falls at the beginning, and whether the starting regimen changes hard clinical events once follow-up titration is allowed.
The Ez-PAVE trial enrolled 3,048 adults in South Korea, a cohort with an average age of 64.4 years, 79.1% men and 20.9% women. Participants were randomized twice in a 2-by-2 factorial design: first to a lower LDL goal of less than 55 mg/dL or a conventional goal of less than 70 mg/dL, and second to initial therapy with statin-ezetimibe combination treatment or statin alone. Across 17 hospitals, the study followed patients for a median of three years and measured cardiovascular death, nonfatal heart attack, nonfatal stroke, any revascularization, and hospitalization for unstable angina.
One sentence captures the main clinical signal: the starting strategy did not change the event curve in a meaningful way.
LDL fell faster with combination therapy, but event rates stayed close
Combination therapy did what lipid pharmacology predicts. Patients who began with statin plus ezetimibe reached lower LDL levels than those who began with statin monotherapy. In the lower-goal group, mean LDL was 53 mg/dL with combination therapy versus 62 mg/dL with statin alone. In the conventional-goal group, mean LDL was 63 mg/dL with combination treatment versus 70 mg/dL with statin alone.
Yet lower LDL numbers at the first checkpoint did not translate into a lower three-year composite event rate. The primary clinical outcome occurred in 8.5% of patients who started with combination therapy and 7.9% of those who started with statin alone. In a study designed around LDL-targeted management, that difference was not statistically meaningful.
The pattern points to a practical bedside lesson. When both groups are treated to target and medications are modified during follow-up, the body may care less about the opening move than about the cumulative time spent near goal. LDL exposure over time drives plaque biology: less circulating atherogenic cholesterol should reduce lipid deposition, slow plaque growth, and stabilize vulnerable lesions. If both groups are brought into the same cholesterol range through protocolized adjustment, the gap in clinical events can narrow quickly.
Protocol-driven titration likely blurred the difference between starting strategies
Many patients who started on statin alone did not remain there. In the lower-goal group, more than 34% eventually had ezetimibe added. In the conventional-goal group, nearly 25% crossed over to combination therapy during follow-up. Those switches were built into the study protocol and allowed in either direction as LDL values dictated, which means the comparison did not test a rigid “always combination” strategy against a rigid “always statin” strategy. It tested two starting points inside an LDL-guided treatment system.
That design is clinically relevant because real-world lipid management often unfolds the same way. Patients begin on a statin, LDL is rechecked, and therapy is intensified if the response is inadequate. Ez-PAVE suggests that this sequence can be a reasonable default in stable atherosclerotic cardiovascular disease when reliable monitoring is available. It also suggests that the value of ezetimibe may be less about the first prescription and more about how efficiently a patient gets to goal.
The lower LDL target itself still mattered. Prior results from the same trial showed that the benefit of the more intensive LDL goal was consistent regardless of the starting drug strategy. In other words, the treatment target retained its importance even though the opening medication choice did not separate outcomes.
Safety was similar across both arms
Side effects and safety concerns were comparable between treatment groups. That is an important finding because upfront combination therapy is sometimes avoided out of concern that adding a second lipid-lowering drug could increase intolerance or complicate routine care. Ez-PAVE did not show a safety penalty that would favor one starting strategy over the other.
The trial was open-label, so patients and clinicians knew which treatment had been assigned. It also took place entirely in South Korea, and about four in five participants were men. Those features limit how directly the results can be extended to more diverse populations. The study was also not specifically powered to detect very small differences between the two starting strategies, and three years may be too short to uncover divergences that emerge only after longer exposure.
Even so, the clinical message is fairly direct. For adults with stable atherosclerotic cardiovascular disease whose LDL is checked regularly and whose treatment can be adjusted to target, starting with a statin and adding ezetimibe as needed appears reasonable. Starting with both drugs may still make sense when LDL is far above goal and clinicians want a faster early reduction, but Ez-PAVE did not show that the upfront combination approach improves three-year cardiovascular outcomes in the setting of active goal-directed titration.
Why the result differs from earlier combination-therapy studies
Kim and colleagues pointed to an important contrast with earlier research. A prior large trial published in the New England Journal of Medicine found benefit when ezetimibe was added to statin therapy, but that study was not primarily structured around achieving a specific LDL target, and medication adjustments were more limited. Ez-PAVE asked a different question: if LDL is repeatedly measured and therapy is adjusted until the target is reached, does beginning with combination therapy improve outcomes beyond starting with statin alone?
The answer, at least over three years in this cohort, was no. That finding fits with the biology of lipid-lowering therapy. Once LDL is driven down and maintained there, incremental differences in how the regimen was started may matter less than the sustained burden of atherogenic lipoproteins over time. For clinicians, the practical consequence is simple: monitor LDL closely, intensify treatment when needed, and do not assume that starting with two agents automatically improves medium-term cardiovascular outcomes in stable disease.
Future work will need to identify which patients, if any, benefit most from immediate combination therapy rather than stepwise intensification. Patients with markedly elevated LDL at baseline may be a different population from those already near target, and the answer may not be the same across risk strata, adherence patterns, or health systems with less frequent follow-up.